COVID-19 疫苗：中和抗体与铝佐剂的优势。
COVID-19 vaccines: neutralizing antibodies and the alum advantage.
机构信息
Texas Children's Center for Vaccine Development, Houston, TX, USA.
Departments of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA.
出版信息
Nat Rev Immunol. 2020 Jul;20(7):399-400. doi: 10.1038/s41577-020-0358-6.
Abstract
Achieving high levels of neutralizing antibodies to the spike protein of SARS-CoV-2 in a safe manner is likely to be crucial for an effective vaccine. Here, we propose that aluminium-based adjuvants might hold the key to this.
摘要
以安全的方式实现对 SARS-CoV-2 刺突蛋白的高水平中和抗体可能是有效疫苗的关键。在这里，我们提出铝基佐剂可能是关键。
相似文献
1
COVID-19 vaccines: neutralizing antibodies and the alum advantage.COVID-19 疫苗：中和抗体与铝佐剂的优势。
Nat Rev Immunol. 2020 Jul;20(7):399-400. doi: 10.1038/s41577-020-0358-6.
2
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.新型冠状病毒灭活疫苗在安全性和免疫原性方面的效果：两项随机临床试验的中期分析。
JAMA. 2020 Sep 8;324(10):951-960. doi: 10.1001/jama.2020.15543.
3
DNA vaccine protection against SARS-CoV-2 in rhesus macaques.DNA 疫苗对食蟹猴 SARS-CoV-2 的保护作用。
Science. 2020 Aug 14;369(6505):806-811. doi: 10.1126/science.abc6284. Epub 2020 May 20.
4
Comparative evaluation of two hemagglutinating encephalomyelitis coronavirus vaccine candidates in mice.两种血凝性脑脊髓炎冠状病毒候选疫苗在小鼠中的比较评估
Clin Vaccine Immunol. 2012 Jul;19(7):1102-9. doi: 10.1128/CVI.05716-12. Epub 2012 Apr 18.
5
Development of an inactivated vaccine candidate for SARS-CoV-2.SARS-CoV-2 灭活疫苗候选物的研发。
Science. 2020 Jul 3;369(6499):77-81. doi: 10.1126/science.abc1932. Epub 2020 May 6.
6
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.评估 mRNA-1273 疫苗对 SARS-CoV-2 在非人类灵长类动物中的效果。
N Engl J Med. 2020 Oct 15;383(16):1544-1555. doi: 10.1056/NEJMoa2024671. Epub 2020 Jul 28.
7
Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.用腺病毒载体和蛋白纳米颗粒进行异源初免-加强免疫接种可诱导针对中东呼吸综合征冠状病毒的 Th1 和 Th2 反应。
Vaccine. 2018 Jun 7;36(24):3468-3476. doi: 10.1016/j.vaccine.2018.04.082. Epub 2018 May 5.
8
Coronavirus vaccines: five key questions as trials begin.新冠病毒疫苗：试验开始之际的五个关键问题。
Nature. 2020 Mar;579(7800):481. doi: 10.1038/d41586-020-00798-8.
9
Differential Immune Responses in Mice Immunized with Recombinant Neutralizing Epitope Protein of Hepatitis E Virus Formulated with Liposome and Alum Adjuvants.用脂质体和明矾佐剂配制的戊型肝炎病毒重组中和表位蛋白免疫小鼠后的差异免疫反应
Viral Immunol. 2016 Jul-Aug;29(6):350-60. doi: 10.1089/vim.2016.0024. Epub 2016 Jun 10.
10
Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.基于类似冠状病毒的实验结果开发 SARS-CoV-2 疫苗的潜在佐剂。
Int Immunopharmacol. 2020 Sep;86:106717. doi: 10.1016/j.intimp.2020.106717. Epub 2020 Jun 18.
引用本文的文献
1
Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.不同COVID-19严重程度等级的肯尼亚SARS-CoV-2感染者中自然诱导的抗SARS-CoV-2抗体结合水平、中和抗体水平及效力的动力学：一项观察性研究
Wellcome Open Res. 2024 Dec 2;8:350. doi: 10.12688/wellcomeopenres.19414.2. eCollection 2023.
2
Non-mucosal vaccination strategies to enhance mucosal immunity.增强黏膜免疫力的非黏膜疫苗接种策略。
Vaccine Insights. 2023 Jul;2(6):229-236. doi: 10.18609/vac.2023.034. Epub 2023 Jul 12.
3
Risk of SARS-CoV-2 transmission in the close contacts in a small rural area in the Veneto Region (NE-Italy): past evidence for future scenarios.新冠病毒在威尼托地区（意大利东北部）一个小村庄密切接触者中的传播风险：过去的证据对未来的情况。
Front Public Health. 2023 Sep 5;11:1223109. doi: 10.3389/fpubh.2023.1223109. eCollection 2023.
4
Antibodies Produced Toward Recombinant RBD and Nucleocapsid Neutralize SARS-COV-2.针对重组受体结合域（RBD）和核衣壳产生的抗体可中和新型冠状病毒（SARS-CoV-2）。
Avicenna J Med Biotechnol. 2022 Oct-Dec;14(4):270-277.
5
Nucleic Acid Vaccines against SARS-CoV-2.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的核酸疫苗
Vaccines (Basel). 2022 Oct 31;10(11):1849. doi: 10.3390/vaccines10111849.
6
Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Randomized Control Trials in the Pre-Delta Era: A Systematic Review and Network Meta-Analysis.新冠病毒变异株德尔塔出现之前时代的随机对照试验中新冠疫苗的疗效、免疫原性和安全性：一项系统评价与网状Meta分析
Vaccines (Basel). 2022 Sep 20;10(10):1572. doi: 10.3390/vaccines10101572.
7
Microneedle Delivery of an Adjuvanted Microparticulate Vaccine Induces High Antibody Levels in Mice Vaccinated against Coronavirus.佐剂微颗粒疫苗的微针递送在接种冠状病毒疫苗的小鼠中诱导产生高抗体水平。
Vaccines (Basel). 2022 Sep 7;10(9):1491. doi: 10.3390/vaccines10091491.
8
Protein-Based Adjuvants for Vaccines as Immunomodulators of the Innate and Adaptive Immune Response: Current Knowledge, Challenges, and Future Opportunities.作为天然免疫和适应性免疫反应免疫调节剂的疫苗蛋白佐剂：当前认知、挑战与未来机遇
Pharmaceutics. 2022 Aug 11;14(8):1671. doi: 10.3390/pharmaceutics14081671.
9
Efficacy and safety of COVID-19 vaccines: A network meta-analysis.COVID-19 疫苗的疗效和安全性：一项网络荟萃分析。
J Evid Based Med. 2022 Sep;15(3):245-262. doi: 10.1111/jebm.12492. Epub 2022 Aug 23.
10
Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave.在首次大流行期间，COVID-19 病例的家庭接触者中轻度 COVID-19 患者的协调固有和 T 细胞免疫应答。
Front Immunol. 2022 Jul 27;13:920227. doi: 10.3389/fimmu.2022.920227. eCollection 2022.
本文引用的文献
1
Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.出版商更正：ChAdOx1新型冠状病毒疫苗可预防恒河猴感染新型冠状病毒肺炎。
Nature. 2021 Feb;590(7844):E24. doi: 10.1038/s41586-020-03099-2.
2
Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.酵母表达的 SARS-CoV 重组受体结合域（RBD219-N1）与氢氧化铝配制而成，可诱导保护性免疫，并降低免疫增强作用。
Vaccine. 2020 Nov 3;38(47):7533-7541. doi: 10.1016/j.vaccine.2020.09.061. Epub 2020 Sep 22.
3
Convergent antibody responses to SARS-CoV-2 in convalescent individuals.恢复期患者体内对 SARS-CoV-2 的趋同抗体反应
Nature. 2020 Aug;584(7821):437-442. doi: 10.1038/s41586-020-2456-9. Epub 2020 Jun 18.
4
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.一种基于重组腺病毒 5 型的 COVID-19 疫苗的安全性、耐受性和免疫原性：一项剂量递增、开放标签、非随机、首次人体试验。
Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22.
5
DNA vaccine protection against SARS-CoV-2 in rhesus macaques.DNA 疫苗对食蟹猴 SARS-CoV-2 的保护作用。
Science. 2020 Aug 14;369(6505):806-811. doi: 10.1126/science.abc6284. Epub 2020 May 20.
6
Rapid COVID-19 vaccine development.新冠疫苗的快速研发。
Science. 2020 May 29;368(6494):945-946. doi: 10.1126/science.abb8923. Epub 2020 May 8.
7
Development of an inactivated vaccine candidate for SARS-CoV-2.SARS-CoV-2 灭活疫苗候选物的研发。
Science. 2020 Jul 3;369(6499):77-81. doi: 10.1126/science.abc1932. Epub 2020 May 6.
8
COVID-19 vaccine design: the Janus face of immune enhancement.COVID-19 疫苗设计：免疫增强的两面性。
Nat Rev Immunol. 2020 Jun;20(6):347-348. doi: 10.1038/s41577-020-0323-4. Epub 2020 Apr 28.
9
The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm.含铝佐剂疫苗的作用机制：体外与体内模式
Springerplus. 2015 Apr 16;4:181. doi: 10.1186/s40064-015-0972-0. eCollection 2015.
10
Airway fibrinogenolysis and the initiation of allergic inflammation.气道纤维蛋白溶解与变应性炎症的起始
Ann Am Thorac Soc. 2014 Dec;11 Suppl 5(Suppl 5):S277-83. doi: 10.1513/AnnalsATS.201403-105AW.
Zotero 插件